Brain Imaging in Elderly People and Individuals With Alzheimer's Disease

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

150 participants

Study Classification

OBSERVATIONAL

Study Start Date

1999-04-30

Study Completion Date

2005-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to use brain imaging technology to study the effects of aging and Alzheimer's Disease (AD) on a specific type of brain receptor.

The brain is made up of cells called neurons. The neurons communicate with one another and secrete chemicals called neurotransmitters. The neurotransmitters bind to specific sites on other neurons called receptors. Acetylcholine (ACh) is a neurotransmitter that binds to ACh receptors. In both aging and AD, the number of neurons that secrete ACh decreases and the function of some ACh receptors changes. This study will use positron emission tomography (PET) scans of the brain to study the effects of age and AD on muscarinic type 2 \[M2\], a type of ACh receptor.

Participants in this study will be injected with a radioactive tracer (ligand \[F-18\] FP-TZTP) which binds to \[M2\] receptors. Participants will then undergo a PET scan in order for the density and function of \[M2\] receptors to be studied.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Evaluation of [18F]APN-1607 PET Uptake in Alzheimer's Disease Patients Compared With Healthy Subjects

NCT04141150

Alzheimer's Disease Mild Cognitive Impairment Due to Alzheimer's Disease Healthy Volunteers

UNKNOWN PHASE2

Evaluation of Age- and Alzheimer's Disease-Related Memory Disorder

NCT00029120

Alzheimer Disease Dementia Memory Disorder +1 more

COMPLETED

PET Imaging of Brain Amyloid Using [11C]MeS-IMPY

NCT00407576

Alzheimer's Disease Healthy

COMPLETED PHASE1

Beta-Amyloid Imaging With [18F]NAV4694 PET in Predicting Progression to AD in Subjects MCI

NCT01812213

Mild Cognitive Impairment

TERMINATED PHASE2

Molecular Cerebral Imaging in Incipient Dementia (MCI-ID) II

NCT02317250

Mild Cognitive Impairment

WITHDRAWN PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The Geriatric Psychiatry Branch (GPB) of the National Institute of Mental Health (NIMH) proposes to study the effect of aging and Alzheimer's Disease (AD) on muscarinic type 2 (M2) receptor density and function using the ligand \[F-18\] FP-TZTP. M2 receptors are primarily autoreceptors found on acetylcholine (ACh) neurons, and are lost along with ACh neurons in aging and AD, particularly in the cerebral cortex. As we near completion of the study of the young versus the old, we would like to add a few more healthy subjects to achieve better gender balance, continue the accrual of Alzheimer's patients and expand the Protocol to include its natural scientific progression. Quantification of M2 receptors with a single FP-TZTP scan as we are currently performing with 99-M-0073 provides a measure of the number of cholinergic receptors in the brain, but not their capacity to release acetylcholine into the synapse. To test this capacity requires a second TZTP scan and the use of an agent that alters acetylcholine concentrations in the synapse. Non-human primate studies performed here (1) have found PET scans with FP-TZTP to be sensitive to changes in acetylcholine synapse concentrations, as a result of competition, in response to the adminstration of the acetylinesterase inhibitor physostigmine. We would like to use physostigmine in all groups; young, older normal, and Alzheimer's patients to infer differences in capacity to release acetylcholine.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Alzheimer's Disease Healthy

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

O15

Intervention Type DRUG

[F-18] FP-TZTP

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Healthy males and females between 20-100 years old and volunteers with AD.

AD volunteers must meet the NINCDS-ADRDA criteria for possible, probable, or definite AD.

All subjects will be required to be off all prescription medications which could effect the PET scan, such as medications with anticholinergic effects, for two weeks to one month prior to the PET scan, and off psychotropic medication for one month.

Subjects will be cautioned not to consume alcohol, marijuana, or psychotropic drugs while on the study, nor to smoke, use caffeinated beverages, or take over-the-counter medications such as cold medications (ie: Benadryl, Sudafed) for at least 12 hours prior to the PET scan.

Exclusion Criteria

Patients withe significant cardiovascular disease, history of alcoholism, significant head trauma, uncontrolled hypertension, diabetes, bleeding disorders or other medical conditions which would make it medically unsafe to perform any part of the PET scan or would confound data analysis.

Subjects with evidence of significant chronic disease to be accepted into the healthy control group.

Subjects must not be pregnant.

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes